The validity and risks of virtually prescribing GLP-1s and their compounded versions is frequently debated. Experts are weighing the benefits and challenges of direct-to-consumer prescribing models versus in-house clinical oversight, along with questions around increased access and affordability with the growing availability of compounded drugs versus the potential dangers with some bad actors and a general lack of FDA-approval. Who is best positioned to prescribe these medications safely and effectively, considering patient outcomes, accessibility, and regulatory implications? Let's have ourselves a GLP-1 debate!